Key result
Hydroxychloroquine linked to ~59% lower congenital heart block recurrence vs historical controls in anti-SSA/Ro-positive mothers.
Why the study?
Macrophage Toll-like receptor signaling is implicated in anti-SSA/Ro-mediated congenital heart block (CHB), but whether the Toll-like receptor antagonist hydroxychloroquine reduces the historical 18% recurrence rate was unknown.
Does hydroxychloroquine reduce the recurrence of congenital heart block in fetuses of anti-SSA/Ro-positive mothers?
Does hydroxychloroquine reduce the recurrence of congenital heart block in fetuses of anti-SSA/Ro-positive mothers?
Hydroxychloroquine 400 mg daily during pregnancy significantly reduces the recurrence of congenital heart block in fetuses of anti-SSA/Ro-positive mothers compared to historical rates.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“At this time, hydroxychloroquine is indicated (based on the recommendations of Izmirly et al) for prophylaxis in patients with a high risk for recurrent fetal congenital heart block because the lifelong risk of morbidity is substantial and probably outweighs the risk of hydroxychloroquine to either mother or fetus. However, they did not recommend the use of hydroxychloroquine in the low-risk population of SSA patients, especially those with low titers and no active disease.”
“Our study shows hydroxychloroquine as the first, safe, and highly effective drug for preventing pregnant women at risk from having another child with congenital heart block.”
“To date, there are no effective therapies once a fetus develops third-degree block and the mortality rate approaches 18% and 70% of children require pacemaker placement. In this open-label prospective trial, hydroxychloroquine 400 mg daily initiated at or before 10 weeks' gestation was associated with a greater than 50% reduction of the recurrence rate of congenital heart block.”
May support HCQ in secondary CHB prevention for anti-SSA/Ro mothers; leaves open confirmatory RCTs before routine adoption.
BACKGROUND Experimental and clinical evidence support the role of macrophage Toll-like receptor signaling in maternal anti-SSA/Ro-mediated congenital heart block (CHB). OBJECTIVES Hydroxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely used in lupus including during pregnancy, was evaluated for efficacy in reducing the historical 18% recurrence rate of CHB. METHODS This multicenter, open-label, single-arm, 2-stage clinical trial was designed using Simon's optimal approach. Anti-SSA/Ro-positive mothers with a previous pregnancy complicated by CHB were recruited (n = 19 Stage 1; n = 35 Stage 2). Patients received 400 mg daily of HCQ prior to completion of gestational week 10, which was maintained through pregnancy. The primary outcome was 2° or 3° CHB any time during pregnancy, and secondary outcomes included isolated endocardial fibroelastosis, 1° CHB at birth and skin rash. RESULTS By intention-to-treat (ITT) analysis, 4 of 54 evaluable pregnancies resulted in a primary outcome (7.4%; 90% confidence interval: 3.4% to 15.9%). Because 9 mothers took potentially confounding medications (fluorinated glucocorticoids and/or intravenous immunoglobulin) after enrollment but prior to a primary outcome, to evaluate HCQ alone, 9 additional mothers were recruited and followed the identical protocol. In the per-protocol analysis restricted to pregnancies exposed to HCQ alone, 4 of 54 (7.4%) fetuses developed a primary outcome as in the ITT. Secondary outcomes included mild endocardial fibroelastosis (n = 1) and cutaneous neonatal lupus (n = 4). CONCLUSIONS These prospective data support that HCQ significantly reduces the recurrence of CHB below the historical rate by >50%, suggesting that this drug should be prescribed for secondary prevention of fetal cardiac disease in anti-SSA/Ro-exposed pregnancies. (Preventive Approach to Congenital Heart Block With Hydroxychloroquine [PATCH]; NCT01379573).
No takes yet. Share an insight, caveat, or question.
Izmirly et al. (2020) studied Congenital heart block (n=63). Hydroxychloroquine vs. Historical control was evaluated on 2° or 3° congenital heart block any time during pregnancy (95% CI 3.4-15.9). Hydroxychloroquine significantly reduced the recurrence of 2° or 3° congenital heart block in fetuses of anti-SSA/Ro-positive mothers to 7.4% compared to a historical recurrence rate of 18%.
Synapse has enriched 10 related papers. Consider them for comparative context: